Licensing Revenue Agreement - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Genentech,Inc. | License And Research Collaboration Agreement
Deferred Revenue Arrangement [Line Items]
Upfront payments received	$ 10.4
Additional upfront payments received	11.0
Transaction price recognized in future	10.4
License revenue recognized	1.0	$ 6.5
Merck & Co., Inc.
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 0.4